Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations
Early Onset Malignancies Initiative (EOMI)
Sponsor: NCI NCORP
Enrolling: Male and Female Patients
IRB Number: AAAR3353
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The primary objective of the EOMI is to acquire tissue and blood, and other biospecimens forresearch purposes from tests performed for clinical care or for research indications on otherresearch protocols to accelerate our understanding of the molecular basis of early onset cancersoccurring in racial and/or ethnic minority populations through the application of genome analysistechnologies, including large-scale genome sequencing and clinical data analysis. Cancers may include breast cancer, colon and rectal cancer, kidney cancer, liver cancer, multiple myeloma, and prostate cancer.
Investigator
Matthew Ingham, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with cancer (breast, kidney, colon, rectal, or liver) or multiple myeloma? Yes No
Are you willing to have your tissue or biologic fluid specimens used for research? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162